Literature DB >> 6256856

Metkephamid, a systemically active analog of methionine enkephalin with potent opioid alpha-receptor activity.

R C Frederickson, E L Smithwick, R Shuman, K G Bemis.   

Abstract

Metkephamid is an analog of methionine enkephalin that retains high affinity for the delta receptor and is a systemically active analgesic. Since it is at least 100 times more potent than morphine as an analgesic when placed directly into the lateral ventricles, and is 30 to 100 times more potent on the delta receptor and yet is roughly equipotent on the mu receptor in vitro, it is concluded that it probably produces analgesia by action on delta receptors as well as, or rather than, on mu receptors. It has less tendency to produce respiratory depression, tolerance, and physical dependence than standard analgesics, and it is presently undergoing clinical trial.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6256856     DOI: 10.1126/science.6256856

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  9 in total

1.  Effects of D-Met2, Pro5-enkephalinamide on pain tolerance and some cognitive functions in man.

Authors:  J I Székely; K Török; I Karczag; J Tolna; M Till
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 3.  The next frontier in the molecular biology of the opioid system. The opioid receptors.

Authors:  O Civelli; C Machida; J Bunzow; P Albert; E Hanneman; J Salon; J Bidlack; D Grandy
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

4.  Opioid receptor subtype-specific cross-tolerance to the effects of morphine on schedule-controlled behavior in mice.

Authors:  R E Solomon; J E Goodrich; J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist.

Authors:  G H Rimoy; D M Wright; N K Bhaskar; P C Rubin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Purification of a membrane-bound metalloendopeptidase from porcine kidney that degrades peptide hormones.

Authors:  R A Mumford; P A Pierzchala; A W Strauss; M Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

7.  Affinities of some common opioid analgesics towards four binding sites in mouse brain.

Authors:  A Neil
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

8.  Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Suneeta Tumati; Josephine Lai; Todd W Vanderah; Henry I Yamamura; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2007-05-22       Impact factor: 7.446

Review 9.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.